Company profile
ViiV Healthcare
Privately held: no public share price
Assets
(13 total)
13Total Assets
6Approved
0Phase 3 / Filed
7Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Cabotegravir(Vocabria / Cabenuva / Apretude) | Approved | HIV integraseSmall molecule | HIV |
Dolutegravir(Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | HIV integraseSmall molecule | HIV |
Fosamprenavir(Lexiva / Telzir) | Approved | HIV proteaseSmall molecule | HIV |
Fostemsavir(Rukobia) | Approved | HIV gp120Small molecule | HIV |
Maraviroc(Selzentry / Celsentri) | Approved | CCR5 co-receptorSmall molecule | HIV |
Rilpivirine(Edurant) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
| Phase 2 | HIV envelopeMonoclonal antibody | HIV | |
| Phase 2 | HIV-1 Gag maturation (CA-SP1 cleavage)Small molecule | HIV | |
| Phase 2 | HIV capsidSmall molecule | HIV | |
| Phase 2 | HIV capsidSmall molecule | HIV | |
| Phase 2 | HIV integraseSmall molecule | HIV | |
| Phase 1 | HIV capsidMultispecific antibody | HIV | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | HIV |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.